Cargando…

Biomarkers of Major Depressive Disorder: Knowing is Half the Battle

Major depressive disorder (MDD) is a heterogeneous disease which is why there are currently no specific methods to accurately test the severity, endophenotype or therapy response. This lack of progress is partly attributed to the complexity and variability of depression, in association with analytic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malik, Sahil, Singh, Ravinder, Arora, Govind, Dangol, Akriti, Goyal, Sanjay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean College of Neuropsychopharmacology 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851463/ https://www.ncbi.nlm.nih.gov/pubmed/33508785 http://dx.doi.org/10.9758/cpn.2021.19.1.12

Ejemplares similares

Transient Insulin Resistance in Propionic Acidaemia: Knowing is half the battle
por: El-Naggari, Mohamed A., et al.
Publicado: (2021)

Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won
por: Tabbò, Fabrizio, et al.
Publicado: (2020)

Fighting sudden cardiac death in India – Knowing your enemy is half the battle
por: Selvaraj, Raja
Publicado: (2016)

Knowing is half the battle: Assessments of both student perception and performance are necessary to successfully evaluate curricular transformation
por: Shaw, Tarren J., et al.
Publicado: (2019)

In pursuit of the right plan for airway management in gastrointestinal endoscopic procedures…the battle half won?
por: Gowd, Upender, et al.
Publicado: (2022)

Surviving COVID-19 is Half the Battle; Living Life with Perceived Stigma is Other Half: A Cross-Sectional Study
por: Bhatnagar, Sushma, et al.
Publicado: (2021)

Commentary: Preparation is half the battle—preclosure devices for peripheral venoarterial extracorporeal oxygenation
por: Laurin, Charles, et al.
Publicado: (2021)

Peripheral Biomarkers in Animal Models of Major Depressive Disorder
por: Carboni, Lucia
Publicado: (2013)

C-Reactive Protein as a Biomarker for Major Depressive Disorder?
por: Orsolini, Laura, et al.
Publicado: (2022)

Applying a Geriatrics Framework to Older Dialysis Patients’ Needs: Getting There Is Half the Battle
por: Potok, O. Alison, et al.
Publicado: (2020)

Boosting regulatory T cell function for the treatment of autoimmune diseases – That’s only half the battle!
por: Schlöder, Janine, et al.
Publicado: (2022)

Endocrine disruption: Battle ground for anesthesia
por: Bajwa, Sukhminder Jit Singh, et al.
Publicado: (2015)

Neuroimaging Biomarkers for Predicting Treatment Response and Recurrence of Major Depressive Disorder
por: Kang, Seung-Gul, et al.
Publicado: (2020)

The Battle for the Soul
por: Tredgold, R. F.
Publicado: (1960)

Battle for the Mind
por: Tredgold, R. F.
Publicado: (1959)

Identifying circulating biomarkers for major depressive disorder
por: Zhang, En, et al.
Publicado: (2023)

A review of new insights into existing major depressive disorder biomarkers
por: Rimti, Fahmida Hoque, et al.
Publicado: (2023)

The Battle of the Clubs
Publicado: (1897)

MicroRNAs as Critical Biomarkers of Major Depressive Disorder: A Comprehensive Perspective
por: Ortega, Miguel A., et al.
Publicado: (2021)

Effects of Antidepressant Treatment on Peripheral Biomarkers in Patients with Major Depressive Disorder (MDD)
por: Mosiołek, Anna, et al.
Publicado: (2021)

The Role of Lipid Biomarkers in Major Depression
por: Parekh, Amy, et al.
Publicado: (2017)

SUMOylation and Major Depressive Disorder
por: Jeoung, Seok-Won, et al.
Publicado: (2022)

Inherited Manganese Disorders and the Brain: What Neurologists Need to Know
por: Kapoor, Dipti, et al.
Publicado: (2021)

Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis
por: Kennis, Mitzy, et al.
Publicado: (2019)

Predictive Biomarkers of Treatment Response in Major Depressive Disorder
por: Stolz, Louise A., et al.
Publicado: (2023)

The battle against perioperative glycaemic control: Hard to win?
por: Parthasarathy, S., et al.
Publicado: (2022)

Neurobiology of Major Depressive Disorder
por: Villanueva, Rosa
Publicado: (2013)

Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide
por: Duman, Ronald S.
Publicado: (2018)

Commentary: Battling the bulge: Buckling staphylomas
por: Kumar, Pradeep, et al.
Publicado: (2022)

Effect of Xiaoyaosan on major depressive disorder
por: Jing, Lin-Lin, et al.
Publicado: (2015)

Epigenetic Modifications of Major Depressive Disorder
por: Saavedra, Kathleen, et al.
Publicado: (2016)

Potential Inflammatory Biomarkers for Major Depressive Disorder Related to Suicidal Behaviors: A Systematic Review
por: Kim, Ka Young, et al.
Publicado: (2023)

Neuroimaging-based biomarkers for treatment selection in major depressive disorder
por: Dunlop, Boadie W., et al.
Publicado: (2014)

Intermediate phenotypes and biomarkers of treatment outcome in major depressive disorder
por: Leuchter, Andrew F., et al.
Publicado: (2014)

Is there Progress? An Overview of Selecting Biomarker Candidates for Major Depressive Disorder
por: Young, Juan Joseph, et al.
Publicado: (2016)

Metabolic and Microbiota Measures as Peripheral Biomarkers in Major Depressive Disorder
por: Horne, Rachael, et al.
Publicado: (2018)

The genetic basis of major depressive disorder
por: Flint, Jonathan
Publicado: (2023)

A Systematic Review of Circulatory microRNAs in Major Depressive Disorder: Potential Biomarkers for Disease Prognosis
por: Rasheed, Madiha, et al.
Publicado: (2022)

Neuroendocrine Biomarkers of Herbal Medicine for Major Depressive Disorder: A Systematic Review and Meta-Analysis
por: Seung, Hye-Bin, et al.
Publicado: (2023)

Dopamine System Dysregulation in Major Depressive Disorders
por: Belujon, Pauline, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_35s7s3hq0kiode0n6m7u6pm583